Reneuron Share Discussion Threads

[babbler] 21/11/2023 16:56

Um.. they said in the recent update they do so...We aim to do this by a variety of means including potentially raising more equity financing and/or securing a financing facility and/or entering into M&A discussions; none of which have been ruled out at the time of writing.

[crt131] 21/11/2023 16:06

Expect a 90% dilution when they issue 500m shares at 2p

[thiopia] 21/11/2023 15:54

This stinks of being shorted into a placing ... which isn't even required given cash position right now

[bigspuds] 15/11/2023 19:43

I'm not saying, this is still a good bet, I still unfortunately hold...drops are all on piddling volume, so it could rise meteorically on a bit of good news like the good old days. Not a recommendation by any means, but a better bet than a lottery ticket (just).

[nigelpm] 28/9/2023 11:35

Option value really at this stage on NOT going bust or getting diluted to high heaven.

[blinddarts] 28/9/2023 08:38

With an average of 65p there was a time when I thought I'd made a very shrewd investment here :o/

[small crow] 04/9/2023 11:14

"..in vivo data.."

[dickbush] 04/9/2023 09:38

We get the news we've been waiting for and sellers are queuing up. I get the feeling I don't have the full picture.

[dickbush] 04/9/2023 08:02

Announcement of the R&D re in vivo testing. The industry presentation is on Wednesday in Boston which will add some meat to the bones.

Thanks.

[thiopia] 04/9/2023 07:53

R&D Update

Creating a valuable and differentiated Exosome Delivery Platform



ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.



Randolph Corteling, Chief Scientific Officer, commented: "I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX™ platform from that of our competitors."



Iain Ross, Executive Chairman, said: "On the basis of this data the Company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads. We look forward to updating shareholders in due course."

[thiopia] 04/9/2023 07:37

RNS out

R&D Update

[thiopia] 01/9/2023 15:09

RENE Reneuron

Share Price : 9.25p
Shares o/s : 57.17m
Mkt Cap : £5.3m



Annual Report (y/e Mar 2023)


"Cash, cash equivalents and bank deposits at 31 March 2023 of £7.2 million"

" Executive Chairman, Iain Ross, commented: “ I remain
very excited about the Company’s potential as we are on course to generate validating data which would allow
us to complete partnering and license deals in the coming year which will transform the Company.”



Data due September/October ( In vivo studies to generate data to further validate the cellular and tissue targeting capabilities and subsequent functional delivery of therapeutic payloads using the CustomEXTM platform are ongoing.

Favourable in vivo data will allow the Group to differentiate its exosome platform and progress
ongoing partnering and licensing discussions. The Board has identified a number of potential sources of
revenue and non-dilutive funding in order to maintain the business as a going concern and is confident it will
be able to conclude third party transactions and/or issue new equity as required. Such transactions will
further strengthen and differentiate our exosomes platform, highlighting our potential leadership in the field.

Technology Overview

ReNeuron’s stem cell derived proprietary exosome technology platform CustomEX™ offers a delivery
mechanism for a variety of potential payloads that could include siRNA, mRNA, proteins, small molecules and
genes.

What are exosomes?
l Naturally occurring biological nano particles produced by every cell to mediate intercellular
communication.
l Can encapsulate various biological molecules within their lipid bilayer membrane or within the lumen of
the Exosome.
l Can be engineered to deliver drug cargos to target cells, offering an opportunity to treat diseases.

The benefits of exosomes
l Proven ability to carry and deliver a variety of cargos including proteins and nucleic acids.
l Potential to deliver more than one bio-active cargo simultaneously.
l Target recipient cells via specific surface proteins that are determined by their cell of origin.
l Low or no immunogenicity, thereby evading immune detection.
Current delivery mechanisms have limitations
l Viral vectors have been plagued by side effect issues and high costs, limitation on the type and size of
cargo they can deliver.
l Lipid nanoparticles (LNPs) have no natural tissue and cell targeting capabilities with delivery therefore
untargeted and mainly to the liver.
l Both have immunogenetic properties that can be problematic.

CustomExTM: A customisable exosome platform
l Seven proprietary conditionally immortalised* exosome producer stem cell lines producing unique
exosome populations.
l ReNeuron’s iPSC platform allows production of exosomes that have the functional properties based on
parent stem cells.
l Capable of delivering a variety of payloads including proteins and nucleic acids and the next generation
for delivery of gene editing technologies.
l Data highlights increased uptake and delivery of payload when compared to a conventional HEK exosome
approach.
l Our CustomExTM exosomes have distinct surface marker profiles (tropisms) enabling a greater tissue
targeting capability.
*Conditional immortalisation of stem cell exosome producer lines offers an elegant solution to not only
consistently produce cell lines that are genetically stable and can be grown at scale, but also to produce a high
yielding source of consistent exosomes for the delivery of complex drug modalities. The standard approach
used by our competitors is to produce exosomes from a single generic cell line. A one-size-fits-all approach.
A single cell line, giving rise to a single outcome.

CSO Randolph Corteling delivering Seminar Presentation in Boston due September 6th

[terminator101] 29/8/2023 08:05

So not only are the Directors pedestrian, they also have a murky past in liquidating companies. Top notch huh.

[dickbush] 22/8/2023 11:30

I went to the AGM this morning. Ex the lawyers I think there may have been five shareholders attending. I asked the question and the answer was, essentially, that there had been a SNAFU on one of the three tests that are running in parallel. We should not read anything into that other than a delay in publishing results. They should now be expected in September/early October.

[thiopia] 21/8/2023 22:34

Probably not at an AGM

They are however presenting at a US Conference in a couple of weeks which would be more suitable forum

[dickbush] 21/8/2023 10:14

In the major presentation to shareholders in May it was stated that the data from the in vivo trials would be available "in two to three months". The meeting tomorrow will be almost three months since that statement. So, are we going to get the results?

[thiopia] 20/8/2023 00:02

("ReNeuron" or the "Company")

Notice of Annual General Meeting

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website here .

The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m.

The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing [e-mail] with your full name and email address. Please note that this email address should be used for this purpose only, and the Registrar will not be able to respond to any other form of communication or enquiry sent to this email address. Persons who have not obtained a QR code in advance will be able to obtain one at the meeting venue.

If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account.

Shareholders are also encouraged to submit any questions for the Chairman to [e-mail] at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at www.reneuron.com.

The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM.

[blackhorse23] 01/8/2023 15:17

Bought HVO

[small crow] 18/7/2023 08:58

I imagine these are buys....

[small crow] 12/7/2023 12:33

Yes. Been the same for some time - indications way out but why...

[dickbush] 12/7/2023 12:19

CFO's buy today is marked as a sell of 52,332 @ 8.949p.

[small crow] 27/6/2023 14:20

IMO don't believe the "buy/sell" indications here today...